Free Trial
→ This stock has 30 days of quiet left (From Behind the Markets) (Ad)tc pixel Free AIKI Stock Alerts

AIkido Pharma (AIKI) Competitors

AIkido Pharma logo
$3.24 +0.01 (+0.31%)
As of 05/22/2026
Compare

AIKI vs. LUNA, DKDCA, JATT, EXOZ, and SKIN

Should you buy AIkido Pharma stock or one of its competitors? MarketBeat compares AIkido Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AIkido Pharma include Luna Innovations (LUNA), Data Knights Acquisition (DKDCA), JATT Acquisition (JATT), eXoZymes (EXOZ), and Beauty Health (SKIN).

How does AIkido Pharma compare to Luna Innovations?

AIkido Pharma (NASDAQ:AIKI) and Luna Innovations (NASDAQ:LUNA) are both small-cap commercial physical research industry companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Luna Innovations had 1 more articles in the media than AIkido Pharma. MarketBeat recorded 1 mentions for Luna Innovations and 0 mentions for AIkido Pharma. Luna Innovations' average media sentiment score of 0.72 beat AIkido Pharma's score of 0.00 indicating that Luna Innovations is being referred to more favorably in the news media.

Company Overall Sentiment
AIkido Pharma Neutral
Luna Innovations Positive

Luna Innovations' return on equity of 0.00% beat AIkido Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
AIkido PharmaN/A -18.21% -16.94%
Luna Innovations N/A N/A N/A

AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Luna Innovations has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market.

Luna Innovations has higher revenue and earnings than AIkido Pharma. AIkido Pharma is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AIkido PharmaN/AN/A-$7.17M-$3.88N/A
Luna Innovations$116.61M0.32$9.28M$0.0336.33

10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 87.5% of Luna Innovations shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by insiders. Comparatively, 7.6% of Luna Innovations shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Luna Innovations beats AIkido Pharma on 10 of the 11 factors compared between the two stocks.

How does AIkido Pharma compare to Data Knights Acquisition?

Data Knights Acquisition (NASDAQ:DKDCA) and AIkido Pharma (NASDAQ:AIKI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Data Knights Acquisition is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Data Knights AcquisitionN/AN/A$340K-$0.19N/A
AIkido PharmaN/AN/A-$7.17M-$3.88N/A

In the previous week, Data Knights Acquisition's average media sentiment score of 0.00 equaled AIkido Pharma'saverage media sentiment score.

Company Overall Sentiment
Data Knights Acquisition Neutral
AIkido Pharma Neutral

Data Knights Acquisition has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market. Comparatively, AIkido Pharma has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Data Knights Acquisition's return on equity of 0.00% beat AIkido Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Data Knights AcquisitionN/A N/A -5.55%
AIkido Pharma N/A -18.21%-16.94%

35.3% of Data Knights Acquisition shares are owned by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are owned by institutional investors. 45.7% of Data Knights Acquisition shares are owned by company insiders. Comparatively, 8.6% of AIkido Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Data Knights Acquisition beats AIkido Pharma on 6 of the 8 factors compared between the two stocks.

How does AIkido Pharma compare to JATT Acquisition?

AIkido Pharma (NASDAQ:AIKI) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AIkido PharmaN/AN/A-$7.17M-$3.88N/A
JATT AcquisitionN/AN/A$6.85MN/AN/A

10.9% of AIkido Pharma shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, JATT Acquisition had 1 more articles in the media than AIkido Pharma. MarketBeat recorded 1 mentions for JATT Acquisition and 0 mentions for AIkido Pharma. AIkido Pharma's average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score.

Company Overall Sentiment
AIkido Pharma Neutral
JATT Acquisition Neutral

AIkido Pharma's return on equity of -18.21% beat JATT Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
AIkido PharmaN/A -18.21% -16.94%
JATT Acquisition N/A -49.58%2.84%

Summary

JATT Acquisition beats AIkido Pharma on 5 of the 6 factors compared between the two stocks.

How does AIkido Pharma compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and AIkido Pharma (NASDAQ:AIKI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

AIkido Pharma's return on equity of -18.21% beat eXoZymes' return on equity.

Company Net Margins Return on Equity Return on Assets
eXoZymesN/A -220.63% -141.26%
AIkido Pharma N/A -18.21%-16.94%

AIkido Pharma has lower revenue, but higher earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eXoZymes$70K1,201.74-$9.16M-$1.14N/A
AIkido PharmaN/AN/A-$7.17M-$3.88N/A

eXoZymes has a beta of 2.85, indicating that its share price is 185% more volatile than the broader market. Comparatively, AIkido Pharma has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
eXoZymes
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
AIkido Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

10.9% of AIkido Pharma shares are held by institutional investors. 72.4% of eXoZymes shares are held by company insiders. Comparatively, 8.6% of AIkido Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, eXoZymes' average media sentiment score of 0.00 equaled AIkido Pharma'saverage media sentiment score.

Company Overall Sentiment
eXoZymes Neutral
AIkido Pharma Neutral

Summary

eXoZymes and AIkido Pharma tied by winning 5 of the 10 factors compared between the two stocks.

How does AIkido Pharma compare to Beauty Health?

AIkido Pharma (NASDAQ:AIKI) and Beauty Health (NASDAQ:SKIN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Beauty Health has a consensus target price of $2.02, indicating a potential upside of 193.73%. Given Beauty Health's stronger consensus rating and higher possible upside, analysts clearly believe Beauty Health is more favorable than AIkido Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AIkido Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Beauty Health
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Beauty Health has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

In the previous week, Beauty Health had 16 more articles in the media than AIkido Pharma. MarketBeat recorded 16 mentions for Beauty Health and 0 mentions for AIkido Pharma. Beauty Health's average media sentiment score of 0.90 beat AIkido Pharma's score of 0.00 indicating that Beauty Health is being referred to more favorably in the news media.

Company Overall Sentiment
AIkido Pharma Neutral
Beauty Health Positive

AIkido Pharma has higher earnings, but lower revenue than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AIkido PharmaN/AN/A-$7.17M-$3.88N/A
Beauty Health$300.80M0.30-$9.52M-$0.17N/A

10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 93.3% of Beauty Health shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by insiders. Comparatively, 40.3% of Beauty Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AIkido Pharma has a net margin of 0.00% compared to Beauty Health's net margin of -2.03%. Beauty Health's return on equity of -9.38% beat AIkido Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
AIkido PharmaN/A -18.21% -16.94%
Beauty Health -2.03%-9.38%-1.21%

Summary

Beauty Health beats AIkido Pharma on 12 of the 15 factors compared between the two stocks.

Get AIkido Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AIKI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIKI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AIKI vs. The Competition

Export
MetricAIkido PharmaCommercial physical research IndustryMedical SectorNASDAQ Exchange
Market Cap$17.77M$22.21M$6.46B$12.34B
Dividend YieldN/AN/A2.76%5.28%
P/E Ratio-0.8318.1721.2225.66
Price / SalesN/A0.32562.2886.31
Price / CashN/A57.2343.4956.67
Price / Book0.170.1710.317.14
Net Income-$7.17M-$525K$3.57B$335.98M
7 Day Performance4.85%3.57%6.43%4.15%
1 Month Performance12.11%-2.23%3.57%2.54%
1 Year Performance-29.57%69.76%34.07%35.06%

AIkido Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AIKI
AIkido Pharma
N/A$3.24
+0.3%		N/A-29.6%$17.77MN/AN/A4
LUNA
Luna Innovations
N/A$1.13
+2.3%		N/A+118.0%$37.53M$116.61M37.67390
DKDCA
Data Knights Acquisition
N/A$0.97
-1.0%		N/A+120.8%$5.02MN/AN/A2
JATT
JATT Acquisition
N/A$10.75
+2.2%		N/A+994.7%$83.85MN/AN/A3
EXOZ
eXoZymes
0.1264 of 5 stars		$9.87
-0.2%		N/A-33.4%$83.77M$70KN/A29

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AIKI) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel